Untitled

[daisydeborahh]

Ordering (Dolutegravir) Tivicay online in Europe is now suitable and secure. Enjoy the ease of accessing a wide range of health products from the comfort of your home. Our platform confirms a seamless and confidential process, providing you with peace of mind. Faith us for reliable and discreet delivery of your needs.

[daisydeborahh]

THE DOLUTEGRAVIR OPPORTUNITY

DTG is a relatively new ARV available in generic form in low- and middle-income countries. It is an integrase inhibitor that blocks an HIV enzyme (a protein that starts or increases the speed of a chemical reaction) called integrase. By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body. As a single dose, in conjunction with other drugs to form a regimen, 50mg DTG single has been on the market in developing countries for a couple of years. However, its relatively high price and unavailability in a triple fixed-dose form limited significant uptake. Botswana, however, was an early adopter of the DTG single through a special initiative of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

In August 2017, the US Food and Drug Administration (FDA) provided tentative approval for two Indian generic ARV suppliers – Aurobindo Pharma and Mylan Laboratories Limited – for the fixed-dose combination of tenofovir 300mg /lamivudine 300mg /dolutegravir 50mg (TLD), reducing one barrier for adoption in developing countries.

[daisydeborahh]

Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages)

HIV treatment has improved greatly over the last two decades and standard of care now involves triple therapy, typically with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus one of the following: a ritonavir-boosted protease inhibitor (PI/r), a non nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor.

Effective antiretroviral treatment (ART) requires high adherence to drug regimes. Development of new ARV medicines often focuses on improvements in tolerability, reductions in toxicity and drug to drug interactions.

Effectiveness of ART is measured by an undetectable viral load. The proportion of treated individuals with a viral load less than 50 has improved (94% in 2016) which may be driven, at least in part, by improvements in drug choice. Current standard treatment is therefore effective for many people. The availability of generic ART has reduced the cost of standard treatment considerably. New drug treatments need to demonstrate both clinical and cost effectiveness over standard treatments.

[daisydeborahh]

Dolutegravir for the treatment of pregnant women living with HIV

HIV, which stands for Human Immunodeficiency Virus, is a retrovirus that causes AIDS (Acquired Immune Deficiency Syndrome). In 2018, a total of 4,026 pregnant women living with HIV were identified, with the indication to start antiretroviral therapy (ART). The timely initiation of ART, with improved adherence and tolerability, is critical for achieving an undetectable viral load, and, consequently, preventing vertical transmission (VT) of HIV.

[daisydeborahh]

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Although the fi rst-generation integrase inhibitors raltegravir and elvitegravir are potent and well tolerated in treatment-naive and treatment-experienced adults with HIV,1–4 improved integrase inhibitor-based therapy options would benefi t these patients. Raltegravir requires twice-daily dosing5 and has variable pharmacokinetic characteristics. Elvitegravir must be taken with food and requires coadministration with a pharmacokinetic boosting agent, creating the potential for clinically signifi cant drug interactions.6 Additionally, treatment-experienced patients who fail raltegravir-based to resistance and has shown potent effi cacy in antiretroviral-naive patients and patients with multiclass resistance.14–16 No signifi cant food eff ect or signifi cant cytochrome P450 inhibition or induction has been observed, suggesting a low potential for interactions.

We report results from ING111762 (SAILING), comparing clinical effi cacy, safety, and virology outcomes in treatment-experienced, integrase-inhibitor-naive patients who received dolutegravir 50 mg once daily or raltegravir 400 mg twice a day, plus investigator-selected background therapy.

[daisydeborahh]

What is dolutegravir?

Dolutegravir is a type of anti-HIV drug called an integrase inhibitor. Dolutegravir is used for the treatment of the HIV, in combination with other anti-HIV drugs. Please speak to your doctor or pharmacist if you would like more information about how these drugs work.